RxDoctor Payments Data

Bibhu Mohanty, MD

Interventional Cardiology · Tampa, FLNPI 1720246242

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 37.2% of the total. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$171,186in general payments, 2019–2025

Across 534 payments — averaging $320.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$64K
  • Boston Scientific$54K
  • Medtronic$28K
  • Abbott$11K
  • Philips North America LLC$3K
  • Edwards Lifesciences$3K
  • plus $8K from 20 others
$134,514in research payments, 2019–2025

Across 14 payments — averaging $9608.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$95K
  • W. L. Gore & Associates, Inc.$25K
  • Gentuity, LLC$13K
  • Medtronic$2K

What the payments were for

  • Consulting fees$77,71345%
  • Speaking & faculty fees$40,09023%
  • Travel & lodging$25,73315%
  • Food & beverage$27,63716%
  • Entertainment$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$171,186 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$164,918
Medicare patients
426
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$79,386
Repatha SureclickEvolocumab36$45,866
XareltoRivaroxaban47$41,317
EntrestoSacubitril/Valsartan23$35,429
Praluent PenAlirocumab12$13,339
Metoprolol Succinate130$2,371
Ranolazine ErRanolazine19$2,061
Atorvastatin Calcium102$1,054
ClopidogrelClopidogrel Bisulfate77$1,012
Carvedilol75$769
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide13$768
Rosuvastatin Calcium81$521
Amlodipine Besylate72$513
Pravastatin Sodium14$498
Valsartan22$494

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →